title: [Myocardial protection and mechanism of Puerarin Injection on patients of coronary heart disease with ischemia/reperfusion].
abstract: OBJECTIVE
  To explore the protective effect and the mechanism of Puerarin Injection (PI) on myocardial ischemia reperfusion in patients with coronary heart disease (CHD) and angina pectoris (AP).
  
  
  METHODS
  Seventy-eight patients with AP planned to receive the PTCA and stenting treatment were randomly divided and single-blindedly into the conventional group and the PI group. Based on the conventional treatment and pre-operational preparation, the PI group was given 200 ml of PI by intravenous dripping once a day, beginning from one week before operation, but to the conventional group, normal saline was given for instead. The condition of AP attack in balloon dilatatory stage of PTCA was observed and change of ST segment of ECG detected by a 12-lead ECG monitor. The blood levels of von Willebrand factor (vWF:Ag), nitric oxide (NO) and endothelin-1 (ET-1) were also observed before and after treatment.
  
  
  RESULTS
  As compared with those in the conventional group, number of patients having AP attack and ST segment change in PTCA process was lessened in the PI group, with blood levels of vWF:Ag and ET-1 obviously lower, and NO content obviously higher than those in the conventional group,
  
  
  CONCLUSIONS
  PI could protect the myocardium in 2-3 days after ischemia reperfusion, one of the possible reasons is that PI can simulate the late phase of ischemic preconditioning, which may be related to its effect in lowering plasma vWF:Ag and ET-1, and increasing the serum NO content.
authors.affiliation: Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang 050000. xieruiqin@hotmail.com
authors.forename: Rui-qin
authors.initials: RQ
authors.lastname: Xie
authors.forename: Jun
authors.initials: J
authors.lastname: Du
authors.forename: Yu-ming
authors.initials: YM
authors.lastname: Hao
mesh_terms: D000787:Angina Pectoris / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000941:Antigens / Q000097:blood; D019332:Endothelin-1 / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007529:Isoflavones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009569:Nitric Oxide / Q000097:blood; D015607:Stents; D014841:von Willebrand Factor / Q000276:immunology
chemical_list: D000941:Antigens; D019332:Endothelin-1; D007529:Isoflavones; C029417:Von Willebrand antigen; D014841:von Willebrand Factor; D009569:Nitric Oxide; C033607:puerarin